Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Dense Rituximab for High Risk Patients With Newly Diagnosed Acute ITP
NCT04323748Phase 1Recruiting
- Sponsor
- New York Medical College
- Start
- Feb 2021
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rituximab in immune thrombocytopenic purpura (ITP), sponsored by New York Medical College. Primary endpoints: Number of participants with treatment-related Grade III or higher adverse events at 1 year and Response Rate at 1 year. Started Feb 2021; status: recruiting.
02
Drugs
rituximab
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT04323748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04323748.